ARGX · Argenx SE
$1,032.86
+39.87 (+4.02%)
At close · Aug 19
Market Cap
$61.75B
Shares
62.19M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1,032.86
Open$1,020.51
Day$1,011.95–1,035.09
52W close$656.89–1,032.86
Avg vol 30d305K
Short int1.3M · 2.1% float · 4.7d
Short vol68%
Last earningsDec 31, 2025
DataJan 2020–Aug 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Moderate
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+24%
above
Price vs 50-day avg
+16%
above
RSI (14)
73
overbought
MACD trend
Positive
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+21%
trailing
6-month return
+34%
trailing
YTD return
+23%
this year
Relative strength
+22%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $888 › 200d $834 — 50d above 200d
Institutional flow
Accumulating
+6% holders QoQ · +83 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.15% of float · ▼ -13.3% MoM · 4.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
506 holders — near 3-yr high, broad support
Squeeze score
60
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
35%
annualized · 1-yr
Max drawdown
−29%
past year
ATR
3.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2024
Combined SG&A and R&D spend
· 2024
$2B
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+24%
Bullish
Price vs 50-day avg
+16%
Bullish
RSI (14)
73
Bearish
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $888 › 200d $834 — 50d above 200d
Institutional flow
Accumulating
+6% holders QoQ · +83 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.15% of float · ▼ -13.3% MoM · 4.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
506 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $657
Now $1,033 · 100%
Range high $1,033
vs 200-day avg +24%
vs 50-day avg +16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ARGX
this stock
Argenx SE
|
$61.75B | +22.8% | — | — | 2.1% |
|
ONC
BeOne Medicines Ltd.
|
$535.83B | +24.0% | +22179.2% | 823.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.88B | +21.8% | +46.2% | 30.8 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.27B | +8.9% | +20.8% | 20.3 | 3.3% |
|
CSLLY
Csl Ltd
|
$56.88B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ARGX | +17.9% | +21.3% | +33.9% | +21.0% | +22.8% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +18.4% | +18.4% | +22.3% | +18.0% | +10.0% |